Trial Profile
A Phase 3, Multicentre, Randomized, Controlled Study to Determine the Efficacy and Safety of Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cyclophosphamide; Dexamethasone; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 30 Jun 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 26 Jun 2023 This trial has been completed in Czechia (End Date: 19 Sep 2019), according to European Clinical Trials Database record.
- 17 Jun 2021 Results of meta-analysis of randomized controlled trials (IFM 2009, EMN02/HOVON 95, RV-MM-EMN-441, RV-MM-PI-209 and FORTE), assessing association of HDT-AHCT with PFS in newly diagnosed high-risk myeloma, with overall survival being the secondary objective, presented at the 26th Congress of the European Haematology Association